首页> 外国专利> METHOD OF ANTI-PLATELET THERAPY IN CARRYING OUT CORONARY ANGIOPLASTY IN PATIENTS WITH ACCUTE MYOCARDIAL INFARCTION

METHOD OF ANTI-PLATELET THERAPY IN CARRYING OUT CORONARY ANGIOPLASTY IN PATIENTS WITH ACCUTE MYOCARDIAL INFARCTION

机译:急性心肌梗死患者进行冠状动脉成形术的抗血小板治疗方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to cardio-vascular surgery. In order to select anti-platelet therapy in carrying out coronary angioplasty in patients with acute myocardial infarction clinical-instrumental and angiographic predictors are determined; their estimation by scale of risk of cardial complications is carried out and therapy volume is determined. In group of clinical-instrumental predictors are included: age, old myocardial infarction, acute impaired cardial function by Killip, diabetes mellitus, revasculisation of myocardium in past, fraction of left ventricle output. In group of angiographic predictors are included: hemodynamically essential lesions of coronary arteries, blood supply type. Point of determined predictors are summed up, risk of cardiac complications are divided into degrees. For risk of first degree, with the sum of points 1-5, coronary angioplasty is carried out at the background of two-component additional anti-platelet therapy, which includes 500 mg of aspirin and 600 mg of clopidogrel. For risk of the second degree, with the sum 6 and more points, coronary angioplasty is carried out at the background of three-component additional anti-platelet therapy, which includes 500 mg of aspirin, 600 mg of clopidogrel and blocker of glycoprotein IIa/IIIa platelet receptors.;EFFECT: method makes it possible to reduce risk of development of hemorrhagic complications by stratification of patients into groups of risk in carrying out coronary angioplasty with stenting.;3 ex
机译:技术领域本发明涉及医学,即心血管外科。为了在急性心肌梗死患者中进行冠状动脉成形术时选择抗血小板治疗,需要确定临床仪器和血管造影预测指标;他们根据心脏并发症风险的等级进行了估算,并确定了治疗量。临床仪器预测因素包括:年龄,老年心肌梗塞,Killip急性心脏功能受损,糖尿病,过去的心肌再血管化,左心室输出量的百分比。一组血管造影预测因素包括:冠状动脉的血流动力学基本病变,供血类型。总结确定的预测因素的要点,将心脏并发症的风险分为程度。对于一级风险,以1-5分的总和,在两组分抗血小板治疗的背景下进行冠状动脉血管成形术,其中包括500 mg阿司匹林和600 mg氯吡格雷。对于第二级风险(总和为6分或更多),在三组分附加抗血小板治疗的背景下进行冠状动脉血管成形术,其中包括500毫克阿司匹林,600毫克氯吡格雷和糖蛋白IIa / IIIa血小板受体。效果:该方法可通过将患者分为在支架置入术中进行冠状动脉血管成形术的危险人群来降低出血性并发症发生的风险。3ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号